FindTrial
Sign In

Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion

DRUG4 trials

Sponsors

Iovance Biotherapeutics Inc., Prinses Maxima Centrum voor Kinderoncologie B.V., Centre Leon Berard

Conditions

MelanomaMetastatic Non-Small-Cell Lung CancerNeuroblastomaNewly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellularclear-cell and tanycytic or anaplastic ependymoma.myxopapillarypapillary

Phase 1

Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma: SIOPEN-Pilot01
RecruitingCTIS2023-509673-22-00
Prinses Maxima Centrum voor Kinderoncologie B.V.Neuroblastoma
Start: 2024-12-02Target: 39Updated: 2025-09-11

Phase 2

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
RecruitingCTIS2024-510778-26-00
Iovance Biotherapeutics Inc.Metastatic Non-Small-Cell Lung Cancer
Start: 2025-12-19Target: 115Updated: 2025-11-26
SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
RecruitingCTIS2024-512222-28-00
Centre Leon Berardclear-cell and tanycytic or anaplastic ependymoma., myxopapillary, Newly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellular +1
Start: 2015-06-02Target: 876Updated: 2024-12-09

Phase 3

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma
RecruitingCTIS2022-503140-41-00
Iovance Biotherapeutics Inc.Melanoma
Start: 2024-11-29Target: 280Updated: 2025-10-31